Besides, shikonin can also potentiate the anti-cancer effects of gemcitabine through NF-kB suppression and by regulating RIP1 and RIP3 expressions in human pancreatic cancer [632, 633]. Here, NFKB1 is linked to pancreatic neoplasm.